Zofran Lawsuit Judge Schedules Next Status Conference Date

December 02, 2015 – – ZofranLegal.com reports on the announcement of the next scheduled status conference dates for Zofran birth defect lawsuits consolidated in the current multidistrict ligtigation in Boston. Two released dates show that the next status conference is quickly approaching, scheduled for December 16th, 2015, while the following conference is currently scheduled for April 14th of 2016.

These status conferences will discuss trial preparations for Zofran birth defect lawsuits, which commonly allege that exposure to the anti-nausea drug through their mothers while developing in utero can cause a fetus to develop severe birth defects. Birth defects connected to Zofran by the plaintiffs include congenital heart defects such as atrial septal defect, ventricular septal defect, transposition of the greater valves, and tetralogy of fallot, as well as other congenital birth defects such as clubfoot, cleft lip and mouth, and kidney defects. According to court documents, the defects have caused death in some infants, and have required multiple surgeries in most.

According to plaintiffs, Zofran was given to combat morning sickness, typically during the first trimester of pregnancy. The first trimester of pregnancy is the most common time to experience nausea associated with morning sickness, however, it is also a time when the fetus does much of its heart, limb, and mouth tissue development. Zofran is regularly prescribed to an estimated 1 million pregnant women each year and has become the most popular morning sickness drug prescribed in Ob/Gyns across the nation.

These facts are especially concerning when those involved realize that Zofran was never approved by the U.S. Food and Drug Administration to treat expectant mothers, or tested for safety on this consumer group. The drug was approved in 1991 specifically to treat patients who were suffering from nausea and vomiting after undergoing radiation therapy, chemotherapy, or anesthesia. After this approval, however, manufacturer GlaxoSmithKline marketed the drug to OB/Gyns and pregnant women nationwide as a treatment for morning sickness. This “off-label” marketing is a topic of much controversy today, and is frequently discussed by current Zofran birth defect lawsuit plaintiffs. It has been alleged that GlaxoSmithKline continued to market the drug in this fashion despite receiving around 200 reports from medical facilities of children being born with severe birth defects.

Today, the lawsuits consolidated in the Massachusetts MDL are expected to be joined by other similar suits as they await trial. During this time, the attorneys at Monheit Law are working to ensure that everyone involved has the opportunity to explore their legal rights. Women who were prescribed Zofran while pregnant and who subsequently gave birth to a child with defects may be entitled to take legal action and obtain significant compensation. Monheit Law is offering free legal consultations to these individuals.

To request additional information on Zofran lawsuits or to ask questions, please contact Attorney Michael Monheit of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005950